Collegium Pharmaceutical, Inc. EPS (Earnings per Share) 2013–2025
Collegium Pharmaceutical, Inc. reported $1.73 of earnings per share for fiscal 2025. That was 7.0% lower than fiscal 2024. Compared with fiscal 2020, the change was +127.6%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $1.73 | -7.0% |
| FY 2024 | $1.86 | +44.2% |
| FY 2023 | $1.29 | +274.3% |
| FY 2022 | $-0.74 | -139.8% |
| FY 2021 | $1.86 | +144.7% |
| FY 2020 | $0.76 | +211.8% |
| FY 2019 | $-0.68 | +42.9% |
| FY 2018 | $-1.19 | — |
| FY 2017 | $0.00 | — |
| FY 2016 | $0.00 | — |
| FY 2015 | $0.00 | — |
| FY 2014 | $0.00 | — |
| FY 2013 | $0.00 | — |
Source: Collegium Pharmaceutical, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open COLL 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Collegium Pharmaceutical, Inc. reported $1.73 of earnings per share for fiscal 2025. That was 7.0% lower than fiscal 2024. Compared with fiscal 2020, the change was +127.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Collegium Pharmaceutical, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCollegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s earnings per share?
Collegium Pharmaceutical, Inc. (COLL) reported earnings per share of $1.73 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.